Skip to main content
Free shipping on all orders
888-559-3802
Shop
Learn
For Practitioners
At-Home Lab Testing
VitabaseGPT
Specials
Go back
VitabaseIngredients

Mangiferin

Table of contents

Other Names

(1S)-1,5-Anhydro-1-(1,3,6,7-tetrahydroxy-9-oxo-9H-xanthen-2-yl)-D-glucitol1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-9H-xanthen-9-one1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]-9H-xanthen-9-one1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]xanthone1,3,6,7-Tetrahydroxyxanthone 2-C-glucoside1,3,6,7-Tetrahydroxyxanthone-C2-β-D-glucoside2-C-β-D-Glucopyranosyl-1,3,6,7-tetrahydroxyxanthone2-β-D-Glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one9H-Xanthen-9-one, 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-Xanthen-9-one, 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy- (9CI)AlpizarinAlpizarineAphloiolChedisarideChinoininChinominChinomineChinoninD-Glucitol, 1,5-anhydro-1-C-(1,3,6,7-tetrahydroxy-9-oxo-9H-xanthen-2-yl)-, (1S)-HedysaridHedysarideMangiferineMangiferolMannipherinNSC 248870QuinonineShamiminXanthone-C-glucoside

Synopsis

Mangiferin: A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

1.1 Names and Classification

Mangiferin (2-C-β-d-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone) is a xanthone C-glycoside occurring in many plant species. Its systematic IUPAC name is 2-(β-d-glucopyranosyl)-1,3,6,7-tetrahydroxy-9H-xanthen-9-one. It is also widely encountered in the literature under the name 1,3,6,7-tetrahydroxyxanthone-C2-β-d-glucoside. The compound carries the CAS Registry Number 4773-96-0 and has a molecular weight of 422.34. Its molecular formula is C₁₉H₁₈O₁₁. Mangiferin is classified as a glucosylxanthone (xanthonoid).

Composed of a glucose unit C1→2 linked to a 1,3,6,7-tetrahydroxyxanthone aglycone, mangiferin exhibits a wide range of biological activities, which recently renewed its interest as a potential pharmacophore. Mangiferin is comprised of a C-glucosylated xanthone; owing to this xanthone chemical structure, it has a redox-active aromatic system and antioxidant properties.

1.2 Natural Sources

Mangiferin was first isolated from the leaves and bark of Mangifera indica (the mango tree). It can also be extracted from mango peels and kernels, Iris unguicularis, Anemarrhena asphodeloides rhizomes, and Bombax ceiba leaves. It is also found in the genera Salacia and Cyclopia, as well as in coffee leaves and some species of Crocus. Mangiferin, a major C-glucosylxanthone from M. indica stem bark, leaves, heartwood, roots, and fruits, occurs widely among different angiosperm families and ferns.

Mangiferin is a natural phytochemical present in various plants, including Anemarrhena asphodeloides, Mangifera indica, and Mangifera persiciformis. A xanthonoid found in mangoes, Iris unguicularis, and Anemarrhena asphodeloides Bunge, mangiferin has been widely used in Chinese traditional medicines for the treatment of diabetes mellitus. Interestingly, among the group of Asplenium hybrids known as the "Appalachian Asplenium complex," mangiferin and isomangiferin are produced only by Asplenium montanum and its hybrid descendants; the distinctive gold-orange fluorescence of these compounds under ultraviolet light has been used to aid in the chromatographic identification of hybrid Aspleniums.

1.3 Related Congeners

Mangiferin is mainly isolated after extraction procedures from natural sources alongside its isoforms isomangiferin, homomangiferin, and neomangiferin. These structural analogs share the core xanthone C-glycoside scaffold but differ in the position of hydroxyl substituents or the nature of the sugar moiety.

1.4 Physical Properties and Forms

Mangiferin presents as a yellow crystalline powder. Studies have reported that the aqueous solubility of mangiferin is relatively low, with a value of only 0.111 mg/mL. In terms of commercial and research preparations, mangiferin is available as a standardized plant extract (most commonly from mango leaves or bark), as an isolated purified compound (typically ≥98% purity by TLC or HPLC), and in experimental nanoparticle- or cyclodextrin-based formulations designed to improve its bioavailability. To address solubility issues, the development of nanoformulations such as nanoparticles, micelles, and liposomes has been explored, which have been proven to improve mangiferin's solubility, stability, and targeted delivery.

2. Traditional and Historical Use

2.1 Ayurvedic and South Asian Traditions

Mangifera indica, also known as mango or aam, has been an important herb in the Ayurvedic and indigenous medical systems for over 4,000 years. For over 4,000 years, various parts of mango trees, including leaf and fruit pulp, have been extensively used in Ayurvedic and Unani medicines. Mangoes belong to genus Mangifera, which consists of about 30 species of tropical fruiting trees in the flowering plant family Anacardiaceae.

According to Ayurveda, varied medicinal properties are attributed to different parts of the mango tree. Aqueous decoctions of mango stem bark have been traditionally used for the treatment of menorrhagia, scabies, diarrhea, syphilis, diabetes, cutaneous infection, and anemia. In Ayurveda, one of its uses is clearing digestion and acidity.

Mango pulp and leaves contain diverse health-promoting chemical constituents including mangiferin, a natural polyphenol of C-glycosylxanthone structure. Mangifera indica trees have been cultivated and grown in Southern and Eastern India for thousands of years and have slowly spread all over the world.

2.2 Traditional Chinese Medicine

Mangiferin, a xanthonoid found in plants including mangoes, Iris unguicularis, and Anemarrhena asphodeloides Bunge, has been widely used in Chinese traditional medicines for the treatment of diabetes mellitus. The rhizomes of Anemarrhena asphodeloides represent one of the most concentrated botanical sources of mangiferin outside the genus Mangifera, and this plant has a long history of use in Traditional Chinese Medicine (TCM) for clearing heat and nourishing yin.

2.3 African and Caribbean Ethnopharmacological Uses

The ethnopharmacological literature details the vernacular names, origin, distribution, taxonomy, and variety of Mangifera indica L. (Anacardiaceae), a medicinal plant traditionally used in tropical regions. Research has documented the ethnopharmacological use of M. indica bark preparations across West and Central Africa and in Caribbean and Latin American folk medicine for febrile illnesses, inflammatory conditions, and as a general tonic. The reported pharmacological activities of mangiferin — including antioxidant, radioprotective, antitumor, immunomodulatory, anti-allergic, anti-inflammatory, antidiabetic, lipolytic, antibone-resorption, monoamine oxidase-inhibiting, antiviral, antifungal, antibacterial, and antiparasitic properties — may support the numerous traditional uses of the plant.

3. Key Constituents, Chemistry, and Mechanisms of Action

3.1 Structural Basis of Bioactivity

Mangiferin (1,3,6,7-tetrahydroxyxanthone-C-2-β-d-glucoside) is a member of the C-glycosylxanthone family and is widely distributed in flowering plants. The C-glycosidic bond — in which the glucose is attached directly to a carbon of the xanthone ring rather than through an oxygen bridge — confers unusual metabolic stability compared with O-glycosides, which are more readily hydrolyzed in vivo. Mango pulp and leaves contain diverse health-promoting chemical constituents including mangiferin, a natural polyphenol of C-glycosylxanthone structure, with diverse pharmacological/physiological activities including the promotion of gut health and regularity, as well as antioxidant and anti-inflammatory benefits.

3.2 Antioxidant Mechanisms

Mangiferin activates the Nrf2/HO-1 pathway and produces antioxidant enzymes like HO-1, SOD, GPx, GST, CAT, GR, and QR, and inhibits ROS production, eventually reducing lipid peroxidation (LPO) and MDA release. The activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) antioxidant response element pathway is among the most consistently documented molecular actions of mangiferin across diverse experimental systems. It has been reported that mangiferin affects the activation or expression of several signaling cascades such as NF-κB, Nrf2/HO-1, and mitochondrial-dependent pathways, and targets several cytokines including interleukin (IL)-6, and antioxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT).

3.3 Anti-Inflammatory Mechanisms

Key advancements in elucidating the molecular action mechanisms of mangiferin have emphasized its role in modulating key signaling pathways such as NF-κB, NLRP3, AMPK, and Nrf2. Research has reported that mangiferin has important roles in anti-inflammation through the suppression of NF-κB and the MAPK signaling pathway in RAW264.7 macrophages, and immunomodulation via regulating the Bregs level and activating the Nrf2 antioxidant pathway.

Mangiferin significantly reduces the production of pro-inflammatory mediators (COX-2, iNOS, and TNF-α) in LPS-stimulated RAW 264.7 cells. It has also been shown to reduce the generation of ROS and inhibit LPS-induced NF-κB translocation in these cells. Additionally, mangiferin significantly reduced inflammation in a mouse air-pouch model by inhibiting the infiltration of monocytes and neutrophils and reducing the production of cytokines. These effects were mediated via inactivation of the NLRP3 inflammasome complex and its downstream signaling molecules.

In terms of mechanism, mangiferin inhibited expression and activation of caspase-1/11 and NLRP3, and blocked cutting of GSDMD and N-terminal domain formation as well as contributed to pyroptosis suppression. Its therapeutic potential encompasses a wide range of inflammation-related disorders, including those affecting the bowel, liver, lung, kidney, brain, and cardiovascular system.

3.4 Metabolic and AMPK-Related Mechanisms

Western blot, real-time PCR, and immunohistochemistry experiments confirmed that mangiferin significantly activates the AMPK signal pathway and inhibits NLRP3 inflammasome activation and pyroptosis. AMPK (AMP-activated protein kinase) activation by mangiferin is considered central to its effects on glucose and lipid metabolism, linking its antidiabetic and hepatoprotective actions to a common upstream regulator. This compound specifically activates PPAR-α luciferase activity in human embryonic kidney 293 cells and enhances PPAR-α-dependent lipoprotein lipase expression and activity in the THP-1-derived macrophage cell line.

3.5 Inhibition of COX-2 and NF-κB

Mangiferin has the potential to modulate multiple molecular targets including nuclear factor-kappa B (NF-κB) signaling and cyclooxygenase-2 (COX-2) protein expression. These two targets intersect with a broad spectrum of inflammatory and oncogenic pathways, partially explaining the wide range of biological activities reported for mangiferin in preclinical models.

3.6 Xanthine Oxidase Inhibition

Mangiferin and its aglycone derivative norathyriol have been investigated as xanthine oxidase (XO) inhibitors. Hypouricemic action of mangiferin results from its metabolite norathyriol via inhibiting xanthine oxidase activity. Results showed that mangiferin at doses of 1.5, 3.0, and 6.0 mg/kg significantly reduced serum urate levels in hyperuricemic mice, compared with untreated hyperuricemic mice. However, mangiferin did not decrease serum urate levels in normal mice until dosing reached 100 mg/kg.

3.7 Neuroprotective Mechanisms

Mangiferin inhibited behavioral abnormalities, oxidative stress, apoptosis, dopaminergic neuronal degeneration, and dopamine depletion caused by MPTP (a Parkinson's disease model neurotoxin), indicating that mangiferin's strong antioxidant and anti-apoptotic qualities were the cause of neuroprotection. The decrease in phosphorylated AMPK ultimately leads to an upregulation of IRF5 expression, promoting the differentiation of microglia into a pro-inflammatory phenotype. This phenotypic shift results in the enhanced secretion of pro-inflammatory cytokines, chemokines, and growth factors by microglia. Mangiferin has been shown to counteract this cascade via the AMPK/mTOR/IRF5 pathway.

4. Scientific Evidence by Area of Use

4.1 Metabolic Syndrome and Lipid Metabolism

Clinical Evidence (Human Studies)

The most robust clinical evidence for mangiferin comes from a double-blind randomized controlled trial in overweight patients with hyperlipidemia. This study sought to evaluate the effects of mangiferin on serum lipid profiles in overweight patients with hyperlipidemia. Overweight patients with hyperlipidemia (serum triglyceride ≥ 1.70 mmol/L, and total cholesterol ≥ 5.2 mmol/L) were included in this double-blind randomized controlled trial; participants were randomly allocated to groups, either receiving mangiferin (150 mg/day) or identical placebo for 12 weeks. A total of 97 participants completed the trial. Compared with the placebo control, mangiferin supplementation significantly decreased the serum levels of triglycerides and free fatty acids (FFAs), and the insulin resistance index.

Evidence strength assessment: This single RCT — while demonstrating statistically significant effects on triglycerides, FFAs, and insulin resistance — represents limited evidence by itself due to its relatively small sample size. No effects on total cholesterol or LDL were clearly reported in this study. Replication in larger and more diverse populations is required before definitive conclusions can be drawn.

Preclinical Evidence

Preclinical laboratory work confirmed that mangiferin had the effects of lowering triglycerides and FFAs in hyperlipidemic hamsters, rats, and HepG2 cell models, which may have been achieved by modulation of the key enzyme expression involved in inhibiting lipogenesis and promoting fatty acid oxidation in the liver.

4.2 Diabetes Mellitus and Blood Glucose Regulation

Preclinical Evidence

The emergence of a worldwide obesity and type II diabetes epidemic has increased focus upon small molecules that can modulate energy metabolism, insulin sensitivity, and fat biology. Interesting preliminary work done on mangiferin (MGF), the predominant constituent of extracts of the mango plant Mangifera indica L., portends potential for this pharmacophore as a novel parent compound for treating metabolic disorders.

In vitro studies have shown that mangiferin inhibited α-amylase activity and α-glucosidase activity, and exhibited promising antidiabetic activities. Animal studies with streptozotocin-induced and alloxan-induced diabetic rat models have consistently shown glucose-lowering and antioxidant effects, though results are not uniformly positive across all experimental designs. One in vivo study found that mangiferin did not reduce glucose and cholesterol concentrations at the doses tested, and concluded that the discrepancy between mangiferin's actual activity and in silico predictions suggests the need for further studies using lower doses of mangiferin and investigating approaches to enhance its bioavailability.

Both combinations of mangiferin with metformin and mangiferin with gliclazide exhibited potent antidiabetic effect in experimental settings. The combination of mangiferin with metformin was insulin-dependent (Akt pathway), whereas the combination of mangiferin and gliclazide was insulin-independent (AMPK pathway).

Mechanism in Diabetic Endothelial Damage

In EA.hy926 cells (a human umbilical vein cell line) exposed to high glucose, mangiferin was demonstrated to effectively inhibit ER stress-associated oxidative stress by attenuating IRE1α phosphorylation, followed by a reduction in ROS production. Furthermore, mangiferin reduced TXNIP expression and NLRP3 inflammasome activation, which eventually inhibited inflammation by reducing IL-1β and IL-6 production. This was followed by an increase in nitric oxide (NO) production, which is beneficial in regulation of endothelial homeostasis, indicating its potential application in the management of diabetic cardiovascular complications.

Evidence strength assessment: Evidence for antidiabetic effects is primarily preclinical (animal and cell-based). No large, well-powered human clinical trials specifically for type 2 diabetes have been published as of the current literature. The field awaits adequately powered randomized controlled trials.

4.3 Non-Alcoholic Fatty Liver Disease (NAFLD) and Hepatoprotection

Mangiferin can significantly attenuate liver injury, insulin resistance, and glucose tolerance in high-fat diet-induced NAFLD mice and significantly reduce fat accumulation and inflammation in hepatic tissue. Transcriptome-level RNA-seq analysis showed that the significantly different expression genes were mainly related to regulation of energy, metabolism, and inflammation in liver tissue. Western blot, real-time PCR, and immunohistochemistry experiments confirmed that mangiferin significantly activated the AMPK signal pathway and inhibited NLRP3 inflammasome activation and pyroptosis in NAFLD mice.

Evidence strength assessment: Evidence for hepatoprotective and anti-NAFLD effects is exclusively preclinical (animal and in vitro). No human clinical trial data for NAFLD have been identified in the current literature. Evidence is preliminary.

4.4 Hyperuricemia and Gout

Mangiferin possesses a variety of biological activities, including antidiabetic, hepatoprotective, anti-inflammatory, antioxidant, and anticarcinogenic properties, and research has explored its hypouricemic potential. Mangiferin is a natural C-glucoside xanthone that commonly exists in young leaves and bark of mango trees. Mangiferin was reported to lower serum uric acid levels and exerts anti-inflammatory, anti-fibrotic, and antioxidative effects in diseases including diabetic nephropathy, acute kidney injury, and NAFLD.

In animal models, these findings demonstrate that mangiferin has the potential to be developed as a new therapeutic agent for the treatment of hyperuricemia and gout. Research into mangiferin's metabolite norathyriol has shown that the hypouricemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity. Additionally, increasing evidence shows that the intestinal tract plays an important role in maintaining urate homeostasis and might be a potential therapeutic target for hyperuricemia. Mangiferin has been studied in this context for its ability to modulate intestinal uric acid transporters.

Evidence strength assessment: Evidence for anti-hyperuricemic effects is currently preclinical only. No human clinical trials investigating mangiferin for gout or hyperuricemia have been identified. Evidence is preliminary.

4.5 Anti-Cancer Activity

The compound targets diverse molecular pathways involved in proliferation, apoptosis evasion, metastasis, and angiogenesis, including NF-κB, MMPs, COX-2, FGF, VEGF, and ICAM. Additionally, mangiferin exhibits chemopreventive properties and synergizes with conventional anticancer agents.

Mangiferin has confirmed potential benefits in lung, cervical, breast, brain, and prostate cancers as well as leukemia, whether administered alone or in combination. However, these findings have been gathered primarily from in vitro cell-line studies and animal models. More clinical trials and research investigations are required to completely unleash the potential of mangiferin, which may lower the risk of cancer onset and act as a preventive and therapeutic alternative for a number of cancers. Clinical translation is hindered by poor oral bioavailability (<2%), necessitating advanced drug delivery strategies.

Evidence strength assessment: All anticancer evidence for mangiferin is currently preclinical (in vitro and animal). No human clinical trial data for any cancer type have been published as of the current literature. Evidence is very preliminary.

4.6 Neuroprotection and Neurodegeneration

Mangiferin exhibits neuroprotective effects against amyloid-β (Aβ) owing to its antioxidant and anti-inflammatory mechanisms. Mangiferin significantly elevates dopamine concentrations. In a Huntington's disease-like animal model, anxiety, decreased recognition memory, reduced locomotor activity, lower neurological scoring, declined rotarod performance, and grip strength that had been triggered by 3-nitropropionic acid were alleviated by mangiferin treatment. A significant depletion in brain malondialdehyde (MDA) level, an increase in reduced glutathione (GSH), succinate dehydrogenase (SDH), superoxide dismutase (SOD) and catalase (CAT) activities, and a decrease in TNF-α, IL-1β, and IL-6 levels were observed in mangiferin-treated groups. Mangiferin also mitigated histopathological alteration in the brain hippocampus, striatum, and cortex sections. It could be inferred that mangiferin protects the brain against oxidative damage and neuroinflammation, notably via antioxidant and anti-inflammatory activities.

Based on these findings, pharmacological agents that can modulate the AMPK/mTOR/IRF5 signaling pathway may inhibit microglial activation, thereby offering significant therapeutic potential for alleviating neuroinflammation and neuronal cell senescence in patients with neurodegenerative diseases, such as Alzheimer's disease.

Evidence strength assessment: Neuroprotective evidence is entirely preclinical (animal models and in vitro). No human clinical trials evaluating mangiferin for Alzheimer's disease, Parkinson's disease, Huntington's disease, or other neurodegenerative conditions have been identified.

4.7 Respiratory and Allergic Conditions

Mangiferin ameliorated nasal symptoms and nasal mucosa inflammation in ovalbumin-induced allergic rhinitis and reduced inflammatory cell infiltration and epithelial disruption in these tissues. Mangiferin inhibited the overproduction of Th2/Th17 cytokines and transcription factors. Mangiferin downregulated the HO-1/Nrf2 pathways, reduced oxidative stress biomarker levels, and the NF-κB signaling pathways were inhibited.

Stress stimuli activate the NLRP3 inflammasome and NF-κB pathway, which triggers TNF-α, IL-1β, IL-6, IL-18, and MCP-1, causing inflammation and eventually lung damage, and mangiferin acts by inhibiting NF-κB and activation of the NLRP3 inflammasome.

Evidence strength assessment: Evidence for effects on allergic rhinitis and respiratory conditions is based on animal models (ovalbumin-challenged mice) and cell studies. No human trials have been identified.

4.8 Cardiovascular Protection

Mangiferin possesses multifactorial pharmacological effects including lipometabolism-regulating and cardioprotective effects. Research has explored mangiferin's potential to protect against myocardial ischemia-reperfusion injury, atherosclerosis, and cardiac inflammation, primarily through its antioxidant and anti-inflammatory actions. Numerous studies confirm that mangiferin, through different mechanisms, has cardiovascular protection activities.

Evidence strength assessment: Cardiovascular evidence is preclinical only. Human clinical data are absent. Evidence is at an early, exploratory stage.

4.9 Antimicrobial and Antiviral Activity

The naturally occurring xanthone glycoside mangiferin has been isolated by column chromatography from the ethanol extract of stem bark of Mangifera indica and studied for antimicrobial properties. Pharmacological activities of mangiferin include antiviral, antifungal, antibacterial, and antiparasitic properties. Preclinical studies have explored activity against herpes simplex virus (HSV), influenza, and HIV. Experiments in a murine model reveal that treatment with mangiferin significantly enhances survival rates in H1N1-infected mice and reduces lung tissue viral titers to one-tenth of control levels at later stages of infection (9 days post-infection).

Evidence strength assessment: Antimicrobial and antiviral evidence is based on cell-based assays and animal studies. No human antiviral or antimicrobial trials have been completed. Evidence is preliminary.

5. Body Systems Associated with Mangiferin Research

Based on the totality of published preclinical and clinical literature, mangiferin has been investigated in relation to the following body systems:

  • Metabolic system: Blood glucose regulation, insulin sensitivity, dyslipidemia, and obesity-related metabolic dysfunction.
  • Hepatic system: Non-alcoholic fatty liver disease, liver injury protection, and lipid accumulation in hepatic tissue.
  • Cardiovascular system: Lipid profile modulation, ischemia-reperfusion protection, and endothelial function.
  • Renal system: Hyperuricemic nephropathy, diabetic nephropathy, and uric acid excretion.
  • Nervous system: Neuroinflammation, neurodegeneration (Alzheimer's disease models, Parkinson's disease models, and Huntington's disease models).
  • Immune system: Immunomodulation, allergic inflammation, and Th2/Th17 cytokine regulation.
  • Respiratory system: Lung inflammation, ARDS models, and allergic rhinitis.
  • Gastrointestinal system: Gastroprotection and gut motility.
  • Oncology (preclinical only): Multiple cancer types studied in vitro and in animal models.

Mangiferin's reported multifactorial pharmacological effects include antidiabetic, antitumor, lipometabolism-regulating, cardioprotective, anti-hyperuricemic, neuroprotective, antioxidant, anti-inflammatory, antipyretic, analgesic, antibacterial, antiviral, and immunomodulatory effects.

6. Pharmacokinetics and Bioavailability

6.1 Absorption and Oral Bioavailability

When it comes to pharmacokinetics and bioavailability, mangiferin is hampered by different obstacles including low solubility and diminished oral bioavailability. The low solubility (0.111 mg/mL) and oral bioavailability (less than 2%) of mangiferin pose significant challenges for its clinical application.

Rats given a 30 mg/kg dose of mangiferin orally exhibited only 1.15% bioavailability; in contrast, rats given the same dose intraperitoneally showed higher absorption. Mangiferin is said to experience strong hepatic first-pass metabolism, which lowers the dosage that enters the systemic circulation.

Mangiferin absorption occurs mostly in the small intestine by passive diffusion with varying absorption capacities in different segments of the gastrointestinal tract. With the use of an in situ intestinal perfusion model, the duodenum > jejunum > colon > ileum was found to have the highest relative permeability (Peff) and absorption rate constant of mangiferin.

6.2 Strategies to Enhance Bioavailability

Recent research has led to the development of novel technologies to encapsulate mangiferin in nano/microparticle carrier systems as well as to generate mangiferin derivatives to improve solubility and bioavailability. There have been reports that complexing mangiferin with β-cyclodextrin (CD) can increase its solubility and bioavailability. The development of nanoformulations such as nanoparticles, micelles, and liposomes has been explored, which have been proven to improve mangiferin's solubility, stability, and targeted delivery. These nanocarriers enhance the bioavailability and therapeutic efficacy of mangiferin, making it a promising candidate for various therapeutic applications.

7. Dosage Forms and Doses Reported in Studies

The following dosages have been reported explicitly in published studies and should be interpreted only in the research context in which they were used:

  • Human RCT (lipid profile): Participants were randomly allocated to groups, either receiving mangiferin (150 mg/day) or identical placebo for 12 weeks.
  • Animal studies (hyperuricemia): Mangiferin at doses of 1.5, 3.0, and 6.0 mg/kg significantly reduced serum urate levels in hyperuricemic mice.
  • Animal studies (anti-inflammatory and hypoglycemic, in vivo rodent): Mangiferin at 50.0 mg/kg and 100.0 mg/kg was administered orally daily for 7 days (in the last week of the experiment) or for 14 days (hypercholesterolemia model).
  • Animal studies (neuroprotection, in vivo): Comparable results were observed in both in vitro (100 nM) and in vivo (10 mg/kg b.w.) ischemia models.
  • Combination therapy (animal model, antidiabetic): Oral intervention of mangiferin with metformin and gliclazide for a period of 28 days was given to diabetic rats.

Low solubility, mucosal permeability, and bioavailability restrict the development of mangiferin as a clinical therapeutic, and chemical and physical modification is required to expand its application. No standardized or consensus human dosage has been established; the only reported human dosage in a controlled trial is 150 mg/day for 12 weeks.

8. Safety, Toxicology, and Interactions

8.1 General Safety Profile

Preclinical studies reported that mangiferin < 2000 mg/kg is generally nontoxic. The safety and the increase in bioavailability are key limiting factors for developing successful applications for mangiferin as a nutritional dietary supplement.

Mangiferin has been reported to be pharmacokinetically and pharmacodynamically stable and non-toxic, with no genotoxic or mutagenic effects in mammalian micronucleus and murine models, at optimized doses. An in vivo experiment on rodents provided evidence that mangiferin in doses of 50 and 100 mg/kg does not exhibit mutagenic properties.

There is no evidence of adverse side effects of mangiferin so far in the clinical trials that have been conducted. However, it is important to note that more human studies are needed to further establish its safety profile in clinical settings.

8.2 Lipinski's Rule Considerations

The molecular structure of mangiferin fulfills the four Lipinski's requisites reported to favor high bioavailability by oral administration. Despite satisfying these theoretical criteria, the empirical oral bioavailability in animal studies remains very low (<2%), highlighting a discrepancy between predicted and actual pharmacokinetic behavior, likely attributable to first-pass hepatic metabolism and P-glycoprotein efflux.

Poor aqueous solubility, poor bioavailability, rapid metabolism, and considerable P-gp efflux can be attributed to its in vivo incompetence.

8.3 Interaction with Pharmaceutical Drugs

Preclinical evidence suggests pharmacodynamic interactions with oral hypoglycemic agents. The combination of mangiferin with metformin was insulin-dependent (Akt pathway), whereas the combination of mangiferin and gliclazide was insulin-independent (AMPK pathway). The overall results suggest that combination of mangiferin with both metformin and gliclazide alleviates diabetic conditions potentially at specific doses and modulates the adverse effects of high-dose commonly used oral hypoglycemic drugs. This combination therapy has been proposed for clinical translation as a diabetes management strategy. These interactions remain to be characterized in human pharmacokinetic studies; formal drug interaction data in humans are not available.

Further clinical research into the pharmacology and pharmacokinetics of mangiferin is required, as most of these effects have only been demonstrated in in vivo and in vitro experiments.

8.4 Nanoformulation Safety Considerations

Understanding the pharmacokinetics of mangiferin-loaded nanoparticles is essential for optimizing dose regimens and evaluating potential toxicity. Comprehensive investigation is necessary to assess the safety and any adverse effects of nanotechnology-based delivery methods. No clinical safety data on nanoencapsulated mangiferin in humans are currently available.

9. Current Research Limitations and Future Directions

Mangiferin has been demonstrated to possess several beneficial properties, including antioxidant, antimicrobial, antidiabetic, antiallergic, neuroprotective, cardiovascular protective, anticancer, hypocholesterolemic, and immunomodulatory effects. Although it has been regarded as a compound with extensive pharmacological activity, the pharmacodynamics of mangiferin remain unclear. Mangiferin appears to have diverse pharmacological effects; however, further clinical research into the pharmacology and pharmacokinetics of mangiferin is required, as most of these effects have only been demonstrated in in vivo and in vitro experiments.

Mangiferin is not being currently applied to clinical use because its oral bioavailability as well as its absorption in the body are too low. Advancing mangiferin toward clinical utility will require the development and rigorous evaluation of delivery systems — such as phospholipid complexes, cyclodextrin inclusion complexes, and polymeric nanoparticles — combined with adequately powered phase II and phase III trials in humans.

Based on the knowledge of the many properties of mangiferin, phytomedicines should be adequately standardized regarding this active compound. More clinical trials should be conducted to support its therapeutic use.

References

Health Conditions

Health conditions that Mangiferin may help support.

  • No conditions available.

Body Systems

Body systems that Mangiferin may help support.

  • No body systems available.
Join our newsletter

Stay informed. Stay healthy.

Get expert supplement tips, exclusive discounts, and product recommendations delivered to your inbox